MEDCu Technologies

Company Overview

Snapshot

Founded in September 2016 by Danny Lustiger and Gadi Borkow, MEDCu Technologies operates with 11–50 employees. The company is in a Pre-Funding stage, focusing on developing advanced wound care solutions. A key milestone for the company was the FDA Premarket Notification for its Medcu Antibacterial Wound Dressings with Copper-oxide in November 2018.

Business overview

MEDCu Technologies is a biotech company specializing in the development of cost-effective antimicrobial wound dressings. Their core product, the MedCu Wound Dressing, incorporates copper microparticles within an absorbent layer and nonwoven external layers, designed to create a barrier against bacterial contamination while promoting healing. These dressings are nonirritating and nonsensitizing, available in various configurations, and are suitable for acute, diabetic, and chronic wounds. The company leverages over 15 years of intensive research in copper particle utilization, protected by more than 30 patents worldwide, serving the health tech and life sciences sectors.

Strategic signal

In October 2021, MEDCu Technologies' innovative copper dressing was highlighted for its effectiveness in treating diabetic wounds. This signals the potential for the company's technology to address significant unmet medical needs in chronic wound care, validating its approach to leveraging copper microparticles for enhanced healing and infection control. For investors, this indicates a strong market opportunity within the medical device and biotechnology sectors, particularly concerning solutions for complex patient populations.

Company Intelligence Q&A

What is MEDCu Technologies' primary product?

MEDCu Technologies' primary product is the MedCu Wound Dressing, a copper-based antimicrobial wound dressing designed to prevent bacterial contamination and support healing for acute, diabetic, and chronic wounds.

When was MEDCu Technologies founded and by whom?

MEDCu Technologies was founded in September 2016 by Danny Lustiger and Gadi Borkow.

Has MEDCu Technologies received any regulatory clearances for its products?

In November 2018, MEDCu Technologies received 510(k) FDA Premarket Notification K180643 for its Medcu Antibacterial Wound Dressings With Copper-oxide.

What is the strategic importance of copper in MEDCu Technologies' products?

MEDCu Technologies utilizes copper microparticles in its wound dressings to provide an antimicrobial barrier against bacterial contamination, a technology developed through over 15 years of research and protected by more than 30 patents globally.

What market need does MEDCu Technologies address?

MEDCu Technologies addresses the need for effective and cost-efficient solutions for managing acute, diabetic, and chronic wounds, leveraging its patented copper-based technology to improve healing outcomes.